Sodium glucose cotransporter (SGLT)-2 inhibitors alleviate the renal stress responsible for sympathetic activation

Area of Science:

• Nephrology
• Cardiology
• Endocrinology

Background:

• Sodium glucose cotransporter (SGLT)-2 contributes to renal dysfunction and heart failure in diabetic patients.
• The reno-cardiac syndrome highlights how kidney injury exacerbates cardiac conditions.
• Sympathetic nervous system overdrive is implicated in this pathogenic process.

Purpose of the Study:

• To review the pathogenic role of SGLT-2 in diabetic reno-cardiac syndrome.
• To propose a mechanistic hypothesis for the benefits of SGLT-2 inhibitors.
• To explore the potential of SGLT-2 inhibitors in non-diabetic renal and heart failure.

Main Methods:

• Review of existing literature, including animal experiments and clinical observations.
• Analysis of the bidirectional interaction between heart and kidney.
• Examination of common pathologies in non-diabetic heart failure patients.

Main Results:

• SGLT-2 contributes to the development of renal dysfunction and heart failure.
• SGLT-2 inhibitors are hypothesized to reduce sympathetic activation at the renal level.
• Renal cortical ischemia and abnormal tubular glucose metabolism are common in non-diabetic heart failure.

Conclusions:

• SGLT-2 plays a pathogenic role in reno-cardiac syndrome.
• SGLT-2 inhibitors may offer therapeutic benefits by modulating sympathetic activity.
• SGLT-2 inhibitors are being investigated for heart and renal failure, even in non-diabetic individuals.